Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Intellia’s in vivo Crispr stays in play, clinically at least
Though broad questions intensify, NTLA-2001 continues showing clinically what it is meant to.
A late Christmas present for Allogene
US clinical hold over Allogene’s entire pipeline has just been lifted.
JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
